Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Super League is redefining brand advertising, inside Roblox and Minecraft, reaching 300M gamers with results traditional ads can't touch. Here's how they do it.
As OpenAI and Anthropic eye public markets, Mizuho analyst Lloyd Walmsley tells us which AI giant has the stronger case for investors and what to watch next.
Hershey's VP of Marketing Dan Mohnshine reveals the brand's newest products, the story behind Dirty Soda Twizzlers, and how an iconic brand stays relevant.
Lavu CEO Saleem Khatri joins to explain how AI-powered POS systems are changing how major franchises like KFC take orders, cut costs, and serve customers faster
BillionToOne's Jen Hoskovec breaks down the Unity test, the latest in prenatal genetic screening, and what it means for those born with genetic conditions.
